Daniil Zhukovsky
Overview
Explore the profile of Daniil Zhukovsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krasavin M, Adamchik M, Bubyrev A, Heim C, Maiwald S, Zhukovsky D, et al.
Eur J Med Chem
. 2022 Dec;
246:114990.
PMID: 36476642
To expand the chemical toolkit for targeted protein degradation, we report the generation of a new series of non-thalidomide Cereblon (CRBN) ligands. Readily available 2-methylidene glutarimide was converted to a...
2.
Zhukovsky D, Darin D, Bakulina O, Krasavin M
Molecules
. 2022 Mar;
27(6).
PMID: 35335391
The reactivity of cyclic α-diazo monocarbonyl compounds differs from that of their acyclic counterparts. In this review, we summarize the current literature available on the synthesis and synthetic applications of...
3.
Krasavin M, Bubyrev A, Kazantsev A, Heim C, Maiwald S, Zhukovsky D, et al.
J Enzyme Inhib Med Chem
. 2022 Feb;
37(1):527-530.
PMID: 35220840
The advent of proteolysis-targeting chimaeras (PROTACs) mandates that new ligands for the recruitment of E3 ligases are discovered. The traditional immunomodulatory drugs (IMiDs) such as thalidomide and its analogues (all...
4.
Krasavin M, Zhukovsky D, Solovyev I, Barkhatova D, Darin D, Frank D, et al.
ChemMedChem
. 2021 Jun;
16(22):3410-3417.
PMID: 34184833
Diversity-oriented synthesis (DOS) is a rich source for novel lead structures in Medicinal Chemistry. In this study, we present a DOS-compatible method for synthesis of compounds bearing a free thiol...
5.
Jovanovic M, Dragoj M, Zhukovsky D, Darin D, Krasavin M, Pesic M, et al.
Front Mol Biosci
. 2020 Nov;
7:586146.
PMID: 33134322
Currently, available glioblastoma (GBM) treatment remains ineffective, with relapse after initial response and low survival rate of GBM patients. The reasons behind limited capacities for GBM treatment are high tumor...
6.
Eremeyeva M, Zhukovsky D, Darin D, Krasavin M
Beilstein J Org Chem
. 2020 Apr;
16:607-610.
PMID: 32280388
-Alkyl α-diazo-γ-butyrolactams, previously found to be unstable and to undergo unproductive dimerization to bishydrazones, were successfully converted immediately to various X-H insertion products with alcohols, aromatic amines and thiols via...
7.
Krasavin M, Sharonova T, Sharoyko V, Zhukovsky D, Kalinin S, Zalubovskis R, et al.
J Enzyme Inhib Med Chem
. 2020 Mar;
35(1):665-671.
PMID: 32131646
A hypothesis that simultaneous targeting cancer-related carbonic anhydrase CA IX and CA XII isoforms (whose overexpression is a cancer cell's defence mechanism against hypoxia) along with thioredoxin reductase (overexpressed in...
8.
Jovanovic M, Zhukovsky D, Podolski-Renic A, Zalubovskis R, Darin D, Sharoyko V, et al.
Eur J Med Chem
. 2020 Feb;
191:112119.
PMID: 32087464
A series of analogs of the earlier reported lead compound DVD-445 (thioredoxin reductase inhibitor with anticancer activity) has been synthesized via a modified Ugi reaction and investigated. Seven most potent...
9.
Jovanovic M, Zhukovsky D, Podolski-Renic A, Domraceva I, Zalubovskis R, Sencanski M, et al.
Eur J Med Chem
. 2019 Aug;
181:111580.
PMID: 31400708
A series of peptidomimetic compounds incorporating an electrophilic moiety was synthesized using the Ugi reaction. These compounds (termed the Ugi Michael acceptors or UMAs) were designed to target the selenocysteine...